



2017 Annual General Meeting

June 19, 2018
Venlo, the Netherlands



1

Opening

Prof. Dr. Manfred Karobath
Chairman of the Supervisory Board



2

Managing Board Report for the year ended December 31, 2017 (“Calendar Year 2017”)



2017 Annual General Meeting

June 19, 2018

Venlo, the Netherlands

Peer M. Schatz


Chief Executive Officer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to "Risk Factors" section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation "Reconciliation of Non-GAAP to GAAP Measures" for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN's GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements.

THE BUILDING BLOCKS OF LIFE: DNA AND RNA



ADDRESSING THE WORLD'S MOST PRESSING CHALLENGES

How can we achieve scientific breakthroughs even faster?


How can we develop better and safer drugs?

How can we improve public safety?

How can we further improve outcomes for patients?

● Expanding the range of customers who can benefit from molecular solutions

CUSTOMERS RELY ON QIAGEN TO MASTER THESE CHALLENGES





● QIAGEN: World leader in molecular testing solutions that enable valuable insights

QIAGEN at a glance

- Leader in molecular testing solutions
- True hybrid covering continuum from Life Sciences to Molecular Diagnostics


Facts and figures

- 2017 sales ~\$1.42 billion
- Customers >500,000
- Global reach >35 countries
- Employees ~4,700
- Share listings Frankfurt / NYSE
- Headquarters Netherlands



● World leader in molecular testing, transforming biological samples into valuable insights


Sales by customer class (As % of annual net sales)




- QIAGEN going through transformation to focus on attractive growth opportunities

2020 ambitions


Net sales



Adjusted EPS



Operating cash flow



- 2020 ambitions: Strong growth in sales, adjusted EPS and cash flow

Key highlight areas: QIAGEN's Sample to Insight portfolio

Life Sciences

Molecular Diagnostics

		Life Sciences	Molecular Diagnostics	
Powered by QIAGEN Bioinformatics		QIAstat-Dx NEW	✓	
		QuantiFERON	✓	
		Next-generation sequencing	✓	✓
		Personalized Healthcare	✓	✓
		QIASymphony	✓	✓
		Differentiated Technologies Applications including: <ul style="list-style-type: none"> ■ Liquid biopsy ■ Microbiome ■ Single-cell research ■ Epigenetics 	✓	✓

● Growth opportunities around Sample to Insight portfolio

Total latent TB
annual addressable
market:

**~70 million
tests**

2017 key achievements

- U.S. launch of 4th-generation QuantiFERON-TB Gold Plus
- New clinical data confirm patient stratification value of new CD8+ technology
- Winning major tenders worldwide – including South Korea and Middle East
- Resolved U.S. patent litigation

~80%

of all NGS runs conducted on
samples processed
with QIAGEN

2017 key achievements

- Exceeded \$115 million CER in annual sales
- Rapid expansion of “digital NGS” QIAseq multiplex gene panel portfolio for use on any NGS sequencer
- GeneReader NGS System
 - Expanding global reach with China MAQGEN joint venture
 - Opening up unlimited content with new customized panel

More than

25

master collaboration
agreements

2017 key achievements

- Exceeded 25 master collaboration agreements with leading pharma and biotech companies
- First-ever NGS-based immuno-oncology Companion Diagnostics consortium with Bristol-Myers Squibb
- First FDA-cleared JAK2 test for blood disorders
- Ongoing growth of PCR-based Companion Diagnostics tests



>2,000

cumulative installed systems
in 2017

2017 key achievements

- Significantly exceeded 2,000 cumulative placements
- Successful regionalization strategy (22 CE-IVD tests, 5 FDA-cleared assays)
- Very positive customer response to new liquid biopsy automation protocols
- New front-end solution for GeneReader NGS System

QIAGEN:

#1

in Sample Technologies

2017 key achievements


- Strengthening No. 1 leadership position in liquid biopsy sample processing
- ~75% market share in microbiome sample processing and full integration of MOBIO technology in new POWER kits
- Absolute leadership in Epigenetics



The total amount of sequence data
doubles
 every 7 months

2017 key achievements

- Strong market leader position in Bioinformatics
- Delivering value to customers with content enabled software
- Discovery segment growing based on microbial solutions and Ingenuity Pathway Analysis (IPA)
- Clinical segment growing based on QIAGEN Clinical Insight and increasing number of international partnerships



European launch of QIAstat-Dx at ECCMID


- Launch with two panels and broad menu pipeline planned
 - System launch with CE-IVD marked respiratory and gastrointestinal panels
 - Menu expansion areas include infectious diseases, oncology and companion diagnostics
- First scientific studies by early adopters presented at ECCMID
 - Inclusivity data for respiratory and gastrointestinal panels for relevant pathogen strains, genotypes and subtypes
 - Platform sensitivity and reproducibility verification for respiratory and gastrointestinal applications
- Acquisition of STAT-Dx closed on April 27

QIAstat-Dx value proposition

Sample to Insight	One-step diagnostic solution
Broad menu	CE-IVD respiratory and gastrointestinal panels at launch, others in development
Ease of use	1-minute hands-on time
Versatility	Sample flexibility for use of swabs and complex liquid samples
Speed	Turnaround time of ~1 hour with full quantification
Safety	Bar code reading and fully self-contained cartridge
Reimbursement	Flexibility in scaling target breadth and test results
Scalability	Modular system (1-8 modules)
Connectivity	Bi-directional HIS / LIS interface
Multi-analyte	Immunoassay capabilities



● QIAstat-Dx adds next-generation Sample to Insight system to QIAGEN's portfolio of core platforms



2018 ambitions

- Sample to Insight portfolio at the forefront of transformation
- Strong focus on execution and improved profitability
- Commitment to increasing returns and creating greater value



Green development

- 384,000 kWh saved at Hilden site by improving air conditioning systems
- Commitment to reduce energy consumption by 10% until 2020

Economic progress

- Certified as one of Germany's "Top Employers 2017"
- Ranked as No.1 brand in image by diagnostic labs

Corporate citizenship

- More than 1,300 hours of volunteer work in the U.S. in 2017
- Biggest volunteer work contribution since beginning of tracking in 2011



Diverse global workforce


- ~4,700 employees
- ~70 nationalities
- ~50% women

Family support

- Kindergarten supporting Hilden employees since 2008
- ~220 children have so far attended the QIAnest Kindergarten

Employee development

- 3,772 employees took part in internal trainings, totaling 7,309 training hours
- Work-life balance with sabbatical programs and flexible work hours




About QIAGEN N.V.


- Organized under the laws of Netherlands
- Listed on NYSE (New York)
- Member of TecDAX Index (Frankfurt)

Endorsing relevant principles

- Application of Dutch Corporate Governance Code
- NYSE – Corporate Governance Rules



Analyst ratings




2017 IR activities


- Private shareholder day: ~30 participants
- Institutional conferences: ~20 events
- Individual meetings: ~650 meetings




QIAGEN share price development – Frankfurt Stock Exchange (euros)



QIAGEN share price development – NYSE (U.S. dollars)




2018 YTD share price performance vs. indices
 (As of June 15, 2018, euros)






2018 YTD: QIAGEN share performance (NYSE)


2018 YTD share price performance vs. indices
(As of June 15, 2018, U.S. dollars)



Share price performance vs. indices
(As of June 15, 2018)



Share price performance vs. indices
(As of June 15, 2018)





Sample to Insight portfolio driving transformation

Moving ahead on sustainable growth and leverage trajectory

Building a strong foundation to excel toward 2020 and beyond

Committed to higher returns and greater value creation



2017 Annual General Meeting

June 19, 2018

Venlo, the Netherlands

Roland Sackers

Chief Financial Officer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to "Risk Factors" section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation "Reconciliation of Non-GAAP to GAAP Measures" for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN's GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements.

1 Achieved full-year 2017 targets

- +7% CER adj. net sales growth excl. business portfolio change vs. ~+7% CER outlook
- \$1.27 adjusted EPS (\$1.27 CER) vs. \$1.25-1.27 CER outlook
- 26% adjusted operating income margin vs. 24% in 2016

2 Sample to Insight portfolio momentum

- Record year for QIASymphony placements
- QuantiFERON-TB sales with 24% growth, new DiaSorin partnership
- NGS achieving \$115 m in annual sales, expanded global reach for GeneReader

3 STAT-Dx acquisition marks entry into multiplex syndromic testing

- Highly synergistic acquisition to drive molecular testing dissemination
- European launch of QIAstat-Dx planned for H2 2018, U.S. launch in 2019 and menu expansion for infectious diseases and oncology

Key results

In \$ millions (Except EPS)	FY 2017	FY 2016	Change \$ / (CER)
Net sales	1,417.5	1,338.0	+6% (+6%)
Adjusted net sales ⁽¹⁾	1,419.4	1,338.0	+6% (+6%)
<i>Adj. net sales excluding business portfolio changes⁽²⁾</i>	1,394.3	1,302.2	+7% (+7%)
Operating income	153.4	98.8	NM
Adj. operating income ⁽³⁾	371.5	324.7	+14%
Net (loss) income	40.4	80.4	NM
Adj. net income ⁽³⁾	295.3	264.8	+12%
Diluted EPS ⁽³⁾	\$0.17	\$0.34	
Adj. diluted EPS (CER) ⁽³⁾	\$1.27 (\$1.27)	\$1.11	+15%

● Full-year 2017: Achieved targets with solid growth of adjusted net sales and adjusted earnings

(1) Adjusted net sales include all revenue contributions from the January 2017 acquisition of bioinformatics company OmicSoft. Organic growth excludes business portfolio changes in both periods.

(2) Business portfolio changes include discontinuation of certain non-core PCR assays and the divestment of China HPV test R&D and commercial distribution to a local company.

(3) Adjusted figures exclude restructuring charges and other items detailed in reconciliation tables. Weighted number of diluted shares (FY 2017: 233.0 million, FY 2016: 239.0 million).

CER – Constant exchange rates NM – Not meaningful Results for net income and EPS based on income attributable to owners of QIAGEN N.V.

(In \$ millions, unless indicated) (Diluted EPS in \$ per share)	Full-year		
	2017	2016	Change
Net sales	1,417.5	1,338.0	6% (6% CER)
Adjusted net sales ⁽¹⁾	1,419.4	1,338.0	6% (6% CER)
Adj. net sales excluding business portfolio changes ⁽²⁾	1,394.3	1,302.2	7% (7% CER)
<i>Gross profit margin</i>	65%	63%	
<i>Adjusted gross profit margin</i>	71%	71%	
Operating income	153.4	98.8	NM
<i>Operating income margin</i>	11%	7%	
Adjusted operating income ⁽³⁾	371.5	324.7	14%
<i>Adjusted operating income margin</i>	26%	24%	
Net income	40.4	80.4	NM
Adjusted net income ⁽³⁾	295.3	264.8	12%
Tax rate	NM	NM	
Adjusted tax rate	18%	16%	
EPS (\$ per share) ⁽³⁾	\$0.17	\$0.34	
Adjusted EPS (CER) ⁽³⁾	\$1.27 (\$1.27)	\$1.11	15%

(1) Adjusted net sales include all revenue contributions from the January 2017 acquisition of bioinformatics company OmicSoft.

(2) Business portfolio changes include discontinuation of certain non-core PCR tests and the divestment of China HPV test R&D and commercial distribution to a local company.

(3) Adjusted figures exclude restructuring charges and other items detailed in reconciliation tables. Weighted number of diluted shares (FY 2017: 233.0 million, FY 2016: 239.0 million).

CER – Constant exchange rates NM – Not meaningful Results for net income and EPS based on income attributable to owners of QIAGEN N.V.

FY 2017 net sales: \$1.418 billion
 FY 2017 adj. net sales: \$1.419 billion

	Adj. Sales (In \$ m)	% CER change	% of sales
Consumables and related revenues	\$1,245	+7%	88%
Instruments	\$175	+1%	12%
Molecular Diagnostics ⁽¹⁾	\$683	+6%	48%
Applied Testing	\$137	+14%	10%
Pharma	\$276	+7%	19%
Academia	\$323	+4%	23%






● Full-year 2017: All customer classes contribute to growth and improved performance

(1) CDx co-development sales (FY 2017: \$43 million, +34% CER); U.S. HPV sales (FY 2017: \$28 million, -16% CER, 2% of sales)
 Growth rates at CER (Constant exchange rates) Sales and sales contributions at actual FX rates Tables may contain rounding differences

FY 2017 net sales: \$1.418 billion
 FY 2017 adj. net sales: \$1.419 billion

	Adj. Sales (In \$ m)	% CER change	% of sales
Americas ⁽¹⁾	\$655	+4%	46%
Europe / Middle East / Africa	\$463	+9%	33%
Asia-Pacific / Japan	\$299	+7%	21%



● Full-year 2017: All regions deliver solid growth, as top 7 emerging markets expand 13% CER

(1) Americas excluding U.S. HPV (FY 2017: +6% CER) Top 7 EGM (FY 2017: +13% CER / 16% of sales); Rest of the world (FY 2017: Less than 1% of net sales)
 Sales figures and sales contributions at actual FX rates Growth rates at CER Tables may contain rounding differences

2017: Reconciliation of reported to adjusted results (U.S. GAAP)

In \$ millions (Except EPS) (unaudited)	Net sales	Gross profit	Operating income	Pretax income	Income tax	Tax rate	Net income	Diluted EPS ⁽¹⁾
Full-year 2017								
Reported results	1,417.5	922.6	153.4	114.4	-74.0	NM	40.4	0.17
Adjustments								
Business integration, acquisition and restructuring-related items (including litigation)	1.9	7.9	105.9	105.9	-31.9		73.9	0.32
<i>Thereof efficiency program</i>		1.4	19.8	19.8	-6.0		13.8	0.06
<i>Thereof U.S. tax reform-related restructuring</i>		3.0	13.8	13.8	-4.3		9.5	0.04
Purchased intangibles amortization		72.7	112.1	112.1	-37.4		74.7	0.32
Non-cash interest expense charges				24.0			24.0	0.10
Other special income and expense (including U.S. tax reform)				2.0	80.2		82.2	0.35
Total adjustments	1.9	80.6	218.1	244.0	10.9		254.9	1.10
Adjusted results	1,419.4	1,003.2	371.5	358.4	-63.1	18%	295.3	1.27


● Full-year 2017: U.S. tax reform prompts need for business integration and restructuring charges

(1) Weighted number of diluted shares (FY 2017: 233.0 million).

Table may have rounding differences. Net income and diluted EPS based on net income attributable to owners of QIAGEN N.V.

Consolidated Income Statements for the year ended December 31, 2017 Reconciliation of net income from IFRS to U.S. GAAP

(In \$ millions)



(1) Under U.S. GAAP Upper Calls are recorded in equity at historical cost; under IFRS Upper Calls are liabilities subject to fair value remeasurement.

(2) IFRS tax results differ from U.S. GAAP for deferred tax on share-based compensation and intercompany transactions.

Consolidated Income Statements for the year ended December 31, 2017

In \$ millions (Except per share data)	U.S. GAAP 2017	IFRS 2017	Difference (U.S. GAAP vs. IFRS)
Net sales	1,417.5	1,417.5	
Gross profit	922.6	912.6	10.0
Income from operations	153.4	156.9	-3.5
Net income	40.4	67.4	-27.0
Earnings per share attributable to equity holders of QIAGEN N.V.			
Weighted average number of common shares, basic	228.1	228.1	
Basic in \$ per share	\$0.18	\$0.30	-\$0.12
Weighted average number of common shares, diluted	233.0	233.0	
Diluted in \$ per share	\$0.17	\$0.29	-\$0.12

● Full-year 2017 results: Institutional investors worldwide assess QIAGEN on U.S. GAAP results

Balance sheet data

(As of December 31)


	2017	2016
Group liquidity (In \$ millions)	1,017	532
Net debt (In \$ millions)	743	537
Shareholder equity ratio	50%	61%
Leverage ratio ⁽¹⁾	1.5x	1.2x

Cash flow

(In \$ millions)

	2017	2016
Net cash provided by operating activities ⁽²⁾	286.8	341.6
Purchases of property, plant and equipment	-90.1	-74.5
Free cash flow ⁽²⁾	196.7	267.1


Leverage ratio⁽¹⁾



● Full-year 2017: Free cash flow of \$197 million impacted by one-time cash payments due to U.S. tax reform


(1) Leverage ratio is calculated on trailing four quarters as net debt / adjusted EBITDA

(2) 2017 results include cash payments for restructuring (FY 2017: \$48 million) and litigation settlements (FY 2017: \$41 million)




● Supporting our business expansion while increasing returns to shareholders

Structure as of December 31, 2017



Maturities of debt instruments

(In \$ millions)



Schuldschein (total volume approx. \$351m):


€34.5 m due 2021 (fix 0.40%, floating 6mEURIBOR + 0.40%)
 €111.0 m due 2022 (fix 0.68%, floating 6mEURIBOR + 0.50%)
 \$45.0 m due 2022 (floating LIBOR + 1.2%)
 €95.0 m due 2024 (fix 1.09%, floating 6mEURIBOR + 0.70%)
 €14.5 m due 2027 (fix 1.61%)

U.S. Private Placement:

\$ 73 m 3.19% notes due 2019
 \$300 m 3.75% notes due 2022
 \$ 27 m 3.90% notes due 2024

Convertible notes:

\$430 m 0.375% due 2019 (\$32.06 effective conversion price)
 \$300 m 0.875% due 2021 (\$32.06 effective conversion price)
 \$400 m 0.500% due 2023 (\$41.41 effective conversion price)



● Digitization: Projects under way to digitize the value chain across all of QIAGEN’s business activities

	Americas	Europe / Middle East / Africa	Asia Pacific / Japan / ROW	Total Q4 2017	Total Q4 2016	Change
Production	279	679	123	1,081	996	9%
R&D	218	691	44	953	995	-4%
Sales	592	718	575	1,885	1,909	-1%
Marketing	66	154	58	278	308	-10%
Administration	90	325	76	491	476	3%
Total	1,245	2,567	876	4,688	4,684	0%

- Full-year 2017: Leveraging marketing synergies and bringing QuantiFERON manufacturing inhouse



Strong focus on execution and performance

2017: Delivered on objectives and created a stronger company

Set to generate strong organic growth and further leverage

Committed to higher returns and disciplined capital deployment




3

- a. Supervisory Board Report on the Company's Annual Accounts (the "Annual Accounts") for Calendar Year 2017
 - b. Report of the Compensation Committee of the Supervisory Board for Calendar Year 2017
-



4

Adoption of the Annual Accounts for Calendar Year 2017
(voting item)



5

Reservation and dividend policy



6

Discharge from liability of the Managing Directors for the performance of their duties during Calendar Year 2017 (voting item)



7

Discharge from liability of the Supervisory Directors for the performance of their duties during Calendar Year 2017 (voting item)



8

Reappointment of the following seven Supervisory Directors of the Company for a one year term ending at the close of the Annual General Meeting in 2019 (voting item)

- a. Mr. Stéphane Bancel
- b. Dr. Håkan Björklund
- c. Dr. Metin Colpan
- d. Prof. Dr. Ross L. Levine
- e. Prof. Dr. Elaine Mardis
- f. Mr. Lawrence A. Rosen
- g. Ms. Elizabeth E. Tallett

Supervisory Board members



Prof. Dr.
Manfred Karobath



Stéphane
Bancel



Dr. Håkan
Björklund



Dr. Metin
Colpan



Prof. Dr. Elaine
Mardis



Prof. Dr. Ross
Levine











Lawrence A.
Rosen



Elizabeth E.
Tallett

- Six new Board members appointed since 2011 with broad range of experience

	Independent	Audit Committee	Compensation Committee	Selection and Appointment Committee	Science and Technology Committee
 Prof. Dr. Manfred Karobath	✓		✓	✓ Chair	✓
 Stéphane Bancel	✓	✓	✓		✓
 Dr. Håkan Björklund	✓		✓	✓	
 Dr. Metin Colpan	✓			✓	✓ Chair
 Prof. Dr. Elaine Mardis	✓				✓
 Prof. Dr. Ross Levine	✓				✓
 Lawrence A. Rosen	✓	✓ Chair			
 Elizabeth E. Tallett	✓	✓	✓ Chair	✓	



Prof. Dr. Manfred Karobath

- Member of the QIAGEN Supervisory Board for 18 years
- Chairman of the QIAGEN Supervisory Board for two years
- Attended more than 90 Board meetings
- Participated in more than 650 hours of meetings

We came a long way since 2000...

- ~4 fold increase in employees: From ~1,300 to more than 4,700 employees
- ~7 fold increase in net sales: From ~\$204 million to more than \$1.4 billion
- ~7 fold increase in share price: From ~\$5, following the burst of the Biotech bubble in 2002, to more than \$37

● From all QIAGENers worldwide, thank you for 18 years of ceaseless commitment and tremendous dedication



9

Reappointment of the following two Managing Directors of the Company for a term ending on the date of the Annual General Meeting in 2019 (voting item)

- a. Mr. Peer M. Schatz
- b. Mr. Roland Sackers



10

Reappointment of KPMG Accountants N.V. as auditors of the Company for the calendar year ending December 31, 2018 (voting item)



11

Authorization of the Supervisory Board, until December 19, 2019 to:

- a. issue a number of Common Shares and financing preference shares and grant rights to subscribe for such shares, the aggregate par value of which shall be equal to the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2017 as included in the Annual Accounts for Calendar Year 2017, (voting item); and
- b. restrict or exclude the pre-emptive rights with respect to issuing shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of twenty percent (20%) of the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2017 (voting item)



12

Authorization of the Managing Board, until December 19, 2019, to acquire shares in the Company's own share capital (voting item)



13

Questions



14

Closing



Thank you

Wir möchten Sie herzlich zu unserem
QIAGEN Private Investor Day 2018

am 28. September, 2018
von ca. 11:00 – 16:00

bei QIAGEN in
Hilden, Deutschland einladen

Kontakt:
Alexandra König
+49 2103 29 11709
E-Mail: alexandra.koenig@qiagen.com

